Checkpoint-insulated triple-signal artificial antigen-presenting cells drive antigen relay and systemic antitumor...

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Dendritic cell (DC) vaccines excel at antigen presentation but have limited lymphoid tissue trafficking.
• Whole tumor cell vaccines offer antigenic diversity but lack T cell activation cues.

Purpose of the Study:

• To develop and evaluate OncoAPC, an artificial antigen-presenting cell designed for enhanced cancer immunotherapy.
• To assess the therapeutic efficacy and mechanism of OncoAPC in preclinical cancer models.

Main Methods:

• OncoAPC was engineered with triple-signal priming logic: MHC-I antigen presentation, CD80 costimulation, and IL-12.
• Mechanistic studies involved assessing T cell activation, PD-1 suppression insulation, and engagement of endogenous DCs.
• Therapeutic efficacy was evaluated in multiple tumor models, comparing OncoAPC to conventional DC vaccination.

Main Results:

• OncoAPC directly activated T cells and partially insulated against PD-1 suppression via CD80:PD-L1 interactions.
• OncoAPC engaged endogenous DCs through cross-dressing, amplifying lymphoid priming.
• OncoAPC demonstrated broad therapeutic activity, suppressing metastatic tumor burden and controlling established tumors, outperforming DC vaccines.

Conclusions:

• OncoAPC represents a scalable cancer vaccine platform integrating antigenic diversity with DC-like precision.
• The artificial antigen-presenting cell platform shows promise for broad-spectrum cancer immunotherapy.
• OncoAPC maintains efficacy across different tumor types and generation methods.